We currently have six ongoing clinical programs and multiple ongoing preclinical programs. In addition, we have completed our Phase 2 trial for acne indication and expect to begin enrolling patients in two Phase 3 studies for this indication in the first half of 2019. Our other five programs are all in Phase 2 development. As of the Latest Practicable Date, over 657 patients have been enrolled in randomized double-blind placebo controlled clinical trials evaluating topical and intranasal routes of delivery of AOB with treatment durations ranging from two to 12 weeks.
The following diagram shows the current stage of development of our product pipeline: